Preliminary Recommendation for the Non-Inclusion of Pertuzumab for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Document link: Pertuzumab for HER2+ Breast Cancer (Proponents may submit appeals to hta@doh.gov.ph until 04 February 2022.) Document Preview: